

25 October 2021
 ASX Code: MXC
 LSE Code: MXC

Dispatch of 2021 Annual General Meeting Documents

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to advise that it has commenced distribution of the accompanying letter to shareholders, advising them of details of MGC Pharma's 2021 Annual General Meeting (AGM) to be held on Wednesday, 24 November 2021 at 4:00pm (AWST) at 1202 Hay Street, West Perth, Western Australia 6005.

Also being dispatched to shareholders today are the Company's Annual Report for the year ended 30 June 2021 and Notice of Annual General Meeting for the AGM.

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd
 Roby Zomer
 CEO & Managing Director
 +61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope
 Andy Thacker
 +44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd
 David Lim
 Company Secretary
 +61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock
 Charles Vivian / Tim Pearson
 +44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels    

25 October 2021

LETTER TO SHAREHOLDERS – UPCOMING ANNUAL GENERAL MEETING

Dear Shareholder,

MGC Pharmaceuticals Ltd (Company) is convening an Annual General Meeting of shareholders on Wednesday, 24 November 2021 at 4:00pm (AWST) at 1202 Hay Street, West Perth, WA 6005.

The Company is continuing to monitor the impact of the COVID-19 virus in Western Australia and following guidance from the Federal and State Governments. Having considered the current circumstances, the Directors have made the decision that a physical meeting will be held. Accordingly, Shareholders will be able to attend the Meeting in person.

In accordance with the Treasury Laws Amendment (2021 Measures No. 1) Act 2021, the Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has requested a hard copy. The Notice of Meeting can be viewed and downloaded from the link set out below.

A copy of the Company's Notice of Meeting released to the ASX on Monday, 25 October 2021 is available to view on the Company's Website at <https://mgcpharma.com.au/investor-centre/asx-announcements/>

The Company plans to conduct a physical meeting on Wednesday, 24 November 2021 at 4:00pm (AWST) at 1202 Hay Street, West Perth, WA 6005, and will also provide a Webinar Facility for Shareholders to view the meeting should you be unable to attend the meeting in person. Details of the Webinar, including detailed instructions on how to access the webinar will be made available to Shareholders on the Company's Website at <https://mgcpharma.com.au/investor-centre/asx-announcements/> as well as being released onto the ASX's Announcement Platform prior to the meeting. The Webinar information once released on the ASX's Announcement Platform will be available to view by navigating to the ASX's Announcement Search function found at the following URL: <https://www.asx.com.au/asx/v2/statistics/announcements.do> and entering the Company's ASX Code "MXC" in the "Search by ASX Code" field to search for the Company's ASX Announcements.

The directors still strongly encourage all shareholders to lodge a directed proxy form prior to the meeting. If you have nominated an email address and have elected to receive electronic communications from the Company, you will also receive an email to your nominated email address with a link to an electronic copy of the important meeting documents.

If you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience. Proxy votes can be lodged with the Company's Share Registry, Computershare Investor Services Pty Ltd online by using the following options:

- Online At www.investorvote.com.au
- By mail Share Registry – Computershare Investor Services Pty Limited, GPO Box 242, Melbourne Victoria 3001, Australia
- By fax 1800 783 447 (within Australia)
+61 3 9473 2555 (outside Australia)
- By mobile Scan the QR code on your proxy form and follow the prompts
- Custodian Voting For Intermediary Online subscribers only (custodians) please visit www.intermediaryonline.com to submit your voting intentions

Your sincerely,

David Lim
Company Secretary